

David T O Yeung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6012702/publications.pdf>

Version: 2024-02-01

33
papers

1,886
citations

566801

15
h-index

454577

30
g-index

33
all docs

33
docs citations

33
times ranked

2126
citing authors

#	ARTICLE	IF	CITATIONS
1	B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification. <i>British Journal of Haematology</i> , 2022, 197, 13-27.	1.2	12
2	Enhancer retargeting of <i>CDX2</i> and <i>UBTF::ATXN7L3</i> define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. <i>Blood</i> , 2022, 139, 3519-3531.	0.6	20
3	Changes in five-year survival for people with acute leukaemia in South Australia, 1980–2016. <i>Medical Journal of Australia</i> , 2022, 216, 296-302.	0.8	6
4	Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4574.	1.8	9
5	Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. <i>Blood</i> , 2022, 139, 3474-3479.	0.6	14
6	A phase 1b study of blinatumomab with the anti-programmed cell death (PD)-1 antibody AMG 404 in adults with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL). <i>Journal of Clinical Oncology</i> , 2022, 40, e19003-e19003.	0.8	1
7	Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. <i>Blood</i> , 2021, 137, 1196-1207.	0.6	48
8	Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 655201.	1.8	7
9	An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. <i>Blood Advances</i> , 2021, 5, 5574-5583.	2.5	6
10	KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease. <i>Cancer Letters</i> , 2020, 469, 410-418.	3.2	29
11	<i>MLLT10</i> rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategies. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 709-721.	1.5	10
12	A costing study of bortezomib shows equivalence of its real-world costs to conventional treatment. <i>British Journal of Haematology</i> , 2020, 189, e76-e79.	1.2	2
13	Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes. <i>Blood</i> , 2020, 136, 46-47.	0.6	4
14	Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. <i>Blood</i> , 2019, 134, 85-89.	0.6	20
15	Compound mutations in CML—imaginary bogeyman or real arch-nemesis?. <i>Leukemia Research</i> , 2019, 81, 102-104.	0.4	3
16	Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. <i>Blood Advances</i> , 2019, 3, 1610-1621.	2.5	27
17	The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1084-1091.	2.5	17
18	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , 2019, 381, 2315-2326.	13.9	257

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of nilotinib 300mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. <i>Leukemia Research</i> , 2018, 67, 109-115.	0.4	11
20	Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. <i>Blood</i> , 2018, 132, 948-961.	0.6	152
21	The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. <i>Blood Advances</i> , 2017, 1, 802-811.	2.5	31
22	The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. <i>Blood</i> , 2016, 127, 1870-1880.	0.6	58
23	Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis. <i>Blood</i> , 2016, 128, 1219-1219.	0.6	2
24	Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study. <i>Blood</i> , 2016, 128, 5447-5447.	0.6	0
25	TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. <i>Blood</i> , 2015, 125, 915-923.	0.6	77
26	RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry. <i>Blood</i> , 2015, 126, 3562-3562.	0.6	0
27	Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 240-243.	0.9	5
28	Prognosis for patients with CML and $\geq 10\%$ BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. <i>Blood</i> , 2014, 124, 511-518.	0.6	182
29	Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. <i>Blood</i> , 2014, 124, 153-155.	0.6	31
30	Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. <i>Blood</i> , 2013, 121, 3818-3824.	0.6	153
31	Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. <i>Blood</i> , 2013, 122, 515-522.	0.6	641
32	BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. <i>Blood</i> , 2012, 119, 4264-4271.	0.6	49
33	Highly sensitive droplet digital polymerase chain reaction for <i>BCR::ABL1</i> messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission. <i>British Journal of Haematology</i> , 0, , .	1.2	2